ArticleAnnals of clinical and translational neurology2021
aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis.
Vivien Häußler et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this paperpooled itcites it